In this study, we investigated the expression of FNDC3B in cancers of 20 different organs and the overall survival related to FNDC3B expression levels in GBM using Oncopression database analysis to validate the potential of FNDC3B as an effective prognostic and therapeutic biomarker for GBM. The gene discussed is FNDC3B; the disease is cancer.